Background and Aims: Increased small intestinal wall thickness correlates with both inflammatory activity and fibrosis in Crohn's disease [CD]. Assessment of perfusion holds promise as an objective marker distinguishing between the two conditions. Our primary aim was to determine if relative bowel wall perfusion measurements correlate with histopathological scores for inflammation or fibrosis in CD. Methods: A total of 25 patients were investigated before elective surgery for small intestinal CD. 
Background
As suggested by Peyrin-Biroulet et al., the severity of Crohn´s disease [CD] includes impact on the patient, inflammatory burden, and complicated disease course. 1 Therefore, the assessment of treatment efficacy has shifted, from either purely clinical endpoints or patientreported impact on quality of life, towards the inclusion of objective evaluation of inflammatory burden. 2 It has been suggested that assessment of treatment response should be based on patient-reported outcomes in combination with absence of ulcerations at endoscopy. 3 Unfortunately, endoscopy only allows assessment of luminal disease and it is mainly useful for evaluation of the colon and terminal ileum. CD limited to the upper small intestine is relatively rare, but often the terminal ileum is not reached during endoscopy. 4 Cross-sectional imaging methods, including magnetic resonance imaging [MRI] , ultrasonography [US] , and computed tomography [CT] , are of paramount importance in the evaluation of small intestinal CD. However, no cross-sectional imaging modality or single parameter is considered gold standard for the purpose. 5 Thus, surgical specimens are regarded as gold standard when evaluating the validity of imaging modalities for transmural assessment and complications. 6 Bowel wall thickness is the most consistently used parameter in cross-sectional imaging, since it is well correlated with disease activity. [6] [7] [8] However, bowel wall thickness does not only correlate with active disease but also with chronic disease or fibrosis. Consequently, bowel wall thickness may reflect burden of disease, rather than active inflammation. The distinction is important because inflammation may respond to medical treatment, whereas fibrosis traditionally is believed not to respond. 9 Active inflammation causes vessel dilatation and neoangiogenesis, resulting in increased blood flow. [10] [11] [12] Contrast enhancement, reflecting blood flow, measured with MRI enterography [MRE] or US, has shown encouraging results as a biomarker for disease activity. [13] [14] [15] [16] [17] [18] However, inconsistent results have been found with regard to the most important parameter for perfusion, 8, 13, 17, 19, 20 and clear correlation with histopathology still needs to be investigated.
For the present study, we hypothesised that the degree of perfusion in segments of the small intestine affected by CD is directly correlated with the histological grading of ongoing inflammatory activity, but inversely correlated with disease chronicity in terms of fibrosis. Thus, our primary objective was to determine the correlation between relative perfusion parameters, and pathology indices of inflammatory activity and fibrosis in small intestinal specimens from patients with CD. Our secondary objectives were to determine correlations between perfusion parameters, and clinical indices or biochemical markers of disease activity.
Material and Methods
This Good Clinical Practice-monitored blinded prospective observational study was approved by our local research ethics committee [1-10-72-339-12] and national Danish authorities [2011-005846-36] . All patients gave written informed consent before participation. Inclusion criteria were patients with known CD scheduled for elective ileo-caecal or small intestinal resection. Additional criteria were age ≥ 18 years and detectable inflammation on US, defined as wall thickness > 3 mm, and/or visualisation of a small intestinal stricture. Exclusion criteria were pregnancy, breastfeeding, or other contraindications for either MRE or contrast-enhanced US [CEUS].
Clinical data
At the time of first US scan, participants reported their age, time since diagnosis of CD, previous abdominal surgery, and type and duration of their present symptoms. The CD Activity Index [CDAI] and Harvey-Bradshaw Index [HBI] were determined, blood samples for inflammatory parameters were drawn, and stool samples were sent for assessment of f-calprotectin.
Dynamic contrast-enhanced ultrasonography
B-mode and CEUS were performed as previously described in detail. 21 In brief, patients were fasting for 4 h before scan. All scans were performed by the same experienced investigator [RW] using an Acuson S3000 [Siemens Medical Solutions, Malvern, PA] and the 9L4 probe. Large ulcers were registered if there were transverse linear hypoechoic regions across the circumferential layered bowel wall pattern or deep impression/concavity in the mucosa, Figure 1 . The bowel segment with the greatest bowel wall thickness and most abundant colour Doppler signal was identified and chosen for the site of CEUS, Figure 2a . US contrast with 2.4 ml sulphur hexafluoride microbubbles [SonoVue®; Bracco Imaging, Milan, Italy], was injected as a bolus followed by 5 ml saline flush, and recorded for 90 s with low mechanical index and fixed acquisition settings, 21 Figure 2b. To ensure blinding to clinical data, post processing was badge-analysed more than 6 months after last US scan, using VueBox® 5.1 [Bracco Suisse SA, Geneva, Switzerland] as earlier described. 21 Mean values of three regions of interests [ROIs] , all larger than 0.1 cm 2 with a quality of fit [QOF] 90% or greater, were used for analysis. Motion compensation was applied whenever appropriate.
Dynamic contrast-enhanced MR enterography
Dynamic contrast-enhanced MRE [DCE-MRE] was conducted after 4 h fasting followed by ingestion of 1 l oral contrast solution. The scanning protocol has been described in detail previously. 21 22 The individual components of the MRI index of activity [MaRIA] score 23 were registered and the total score was calculated.
Using a home-written programme in MATLAB® [MathWorks®, Natick, MA], the dynamic sequences were analysed for the most severely affected segment defined by the radiologist ([neo-]terminal ileum or proximal small bowel). A region of interest [ROI] was drawn inside the bowel wall at the most enhanced part, Figure 2 . The ROI was manually moved in order to stay within the bowel wall during the dynamic scan. 21 
Standardised tissue preparations and histopathology analyses
Immediately after surgical resection, the bowel segment was rinsed in tap water. To preserve the luminal diameter and allow direct comparison with images, we did not open the bowel segment longitudinally. Fixation was in neutral buffered formaldehyde for 48 h using intraluminal wicks to aid fixative permeation. Wellfixed specimens were transversely sectioned in 3-6 mm slices and digitally photographed, before several blocks were selected representing most stenotic part, most inflamed part, and other diagnostic findings. Large slices were embedded in total in macro blocks to ensure full cross-sectional coverage of the bowel. For examination of the smallest lumen and the largest wall thickness for each patient, sections of 3 μm were stained with haematoxylin and eosin stain and Masson trichrome stain, respectively. If this occurred in two different blocks, two were examined. All slides were digitalised with a NanoZoom 2.0 HT Digital Slide scanner and, for slides from macro blocks, using a NanoZoomer 2.0-RS Digital slide scanner [both Hamamatsu, Hamamatsu City, Japan]. Glasses where examined by a senior gastrointestinal pathologist [RHH] and active inflammation was scored as previously described by Borley et al. 24 . In brief, the score semi-quantitatively describes acute inflammation based on grading mucosal ulceration [0-3], edema [0-3], and depth of neutrophilic infiltration [0-4]. Chronic inflammation was scored according to Chiorean et al. 25 Depth of collagen deposition was scored as described by Baumgart et al. 26 with an increasing score related to the layers with increased deposition [0] [1] [2] [3] [4] [5] . Bowel wall thickness was digitally measured as the greatest measurement of three in the NDP. view2 Viewing software U12388-01, by RW more than 6 months from initial US scan so as to be effectively blinded [Hamamatsu, Hamamatsu City, Japan], Figure 2 . 
Statistical methods
Non-computer analysed data were registered in web-based databases by REDCap. 27 Data from VueBox, REDCap, and MATLAB were exported in csv-format. Statistical analysis was performed with Stata for Mac 13.1 [Stata Corp LP, College Station, TX]. If no detectable disease could be found on MRE, bowel wall thickness was registered at 3 mm with a length of 0 cm. None of the linearised CEUS intensity data, expressed as arbitrary intensity units [AIU], followed a Gaussian distribution. Hence, they were log-converted as by default in US systems using 10 x log10 [AIU] and expressed in dB for further analysis. 18, 21 Agreement between bowel wall thickness, US and MRE was described with 95% limits of agreement [LoA] 
Results
In all, 25 consecutive patients with known CD were recruited between October 2012 and March 2014 from the colorectal surgical department of Aarhus University Hospital, a tertiary referral centre.; 23 patients underwent CEUS and DCE-MRE on the same day, and two had their DCE-MRE performed 3 and 4 days later, respectively. No patients experienced any severe adverse events. Elective surgery was performed in a median of 7 days from the US scan [range 1-26 days]. Only seven patients had surgery more than 14 days from CEUS. Of those patients, two were on stable budesonide for more than 3 months, one on azathioprine for 9 months and oral steroids for 1 month, two were on adalimumab for 1.5 and 5 years, respectively, and finally two were without treatment. No change in treatment occurred between CEUS and surgery: see Figure 3 for eligible and included patients and Table 1 for full demographics.
Patho-anatomical data
Bowel wall thickness measured on histopathology was 8.7 ± 1.6 mm, on US 9.1 ± 2.1 mm, and on MRE 10.0 ± 2.6 mm. US measurements were 0.4 (95% confidence Table 2 . Compared with patients without ulcers, patients with histologically proven ulcers had a thicker bowel wall; 9. Table 3 .
For secondary endpoints, there was weak to moderate correlation between CEUS intensity parameters and f-calprotectin [r = 0.49, p = 0.017], Figure 4 . However, no statistical significant correlation was present between CEUS and CDAI, HBI, or C-reactive protein.
DCE-MRE showed a moderate to weak inverse correlation to CDAI that was statistically significant for peak enhancement and area under curve at 25 and 70 s. Also, an inverse correlation was found for area under curve at 70 s and HBI. However, there was no correlation between DCE-MRE and biochemical markers of activity. For all results on perfusion parameters, see Table 4 . 
Post-hoc analyses of MR enterography global score, MR index of activity, and bowel wall thickness

Discussion
In the present study, unenhanced and dynamic contrast-enhanced US and MRE were compared with histopathological descriptions of resections, which are generally considered the gold standard for assessment of transmural inflammation and fibrosis in CD. Our main findings do not suggest any direct correlation between relative perfusion parameters and the applied histological classification. However, there were indications towards direct correlations between f-calprotectin and CEUS and between CDAI and DCE-MRE. Additionally, we find good agreement between histology and the appreciation of bowel wall thickness and ulcers on cross-sectional imaging, especially US. US may be superior to MRE in measuring wall thickness, owing to the higher resolution and the ability to angle scan plane to assess the bowel wall in true cross-section. Thus, increased bowel wall thickness still seems to be the single most important factor when assessing both activity and chronicity of small intestinal CD.
Although not true for all CD patients, the disease course is considered progressive from inflammation to stricture and/or penetrating disease behaviour. 28 There is common belief that successful medical treatment is possible against active inflammation but not the chronic fibrotic disease stage. 29, 30 Since inflammation precedes and drives fibrosis, 31 early aggressive treatment may be beneficial. 32, 33 This calls for non-invasive objective modalities able to map the small No., number; US, ultrasonography; IBD, inflammatory bowel disease. Numbers in brackets are percentages or ranges. Unless indicated otherwise, data are means ± standard deviations.
a Median values and ranges. intestine and distinguish between the two conditions. Furthermore, objective evaluation of efficacy is important during the course of treatment. 34, 35 In recent years, intestinal perfusion has been suggested as a marker to reflect disease activity. [36] [37] [38] However, most of the previous studies used clinical markers like CDAI 39 and HBI, or pseudo markers of activity like C-reactive protein, f-calprotectin, 40 or CD34 count of mucosal biopsies, 17 or even compared CEUS with MRE without acknowledging that neither is considered gold standard. 5 Some authors have used endoscopic indices, but only to distinguish between active and no inflammation rather than to grade activity. 8, 15, 40 We applied histology from the most severely affected part of the specimen as the gold standard for inflammation and fibrosis. Activity was measured by the score from Borley et al. 24 and fibrosis by Chiorean et al. 25 These scores were previously applied by Ripollés et al. 41 and showed a moderate correlation with CEUS. However, theirs was a combined score including several variables, including wall thickness and an arbitrary contrast intensity increase of > 46%. The same score had an almost identical correlation with fibrosis. The likely component of this correlation could therefore be wall thickness, which we also found had a moderate correlation with both activity and fibrosis. Romanini et al. 17 used a rather vague histological description and divided patients into two categories; active and inactive. They found a good correlation to several perfusion parameters. However, the analyses were performed on biopsies, rather than transmural specimens. Nylund et al. 42 compared patients undergoing surgery with patients in medical treatment, and defined the surgical group to be mainly fibrostenotic by excluding 10% of patients without significant fibrosis. They found significantly lower bowel wall blood volume in the surgery group.
We only recruited patients undergoing surgery, and the patient group was highly heterogeneous in terms of histopathology indices, f-calprotectin, CDAI, and perfusion parameters. Still, we are not able to show any significant correlation. Our choice of gold standard is debatable, since the acute inflammatory score was not designed for this purpose 24 and has not been validated. This also Pathological findings according to fibrosis index by Chiorean et al., 25 and acute inflammation index by Borley et al. 24 Numbers in brackets are percentages.
accounts for the fibrosis score. It is unfortunate that histology is considered the gold standard for transmural disease without having a solid validated score. 43 This paradox further impedes other pseudo-markers of activity like CEUS and DCE-MRE. The best existing activity index may thus be the Simplified Endoscopic Activity Score for CD 44 [SES-CD] or CD Endoscopic Index of Severity 45 [CDEIS], with the latter being less reproducible. 46 These indices are, however, restricted to the mucosa and unless double balloon endoscopy is performed, they are limited to the large intestine and terminal ileum.
In our secondary outcomes, we found a moderate correlation between CEUS and f-calprotectin, a pseudo-marker for active inflammation. This could suggest that the chosen histological scores were inadequate. In contrast to previous studies, we found that DCE-MRE had an inverse correlation with CDAI which contradicts what was earlier shown. 47, 48 However, CDAI is now considered less useful and sometimes unreliable to assess disease activity. 49 Although Giusti et al. 48 found complete match between active disease based on CDAI and mucosal biopsies, six patients in our study, having CDAI < 150, underwent surgery with severely increased bowel wall thickness and thus a large element of pathological changes.
In our post-hoc analysis, existing MRE scores of CD activity showed a moderate correlation with the acute activity index for the MEGS score. Depth of collagen deposition correlated weakly with both MEGS and the MaRIA score. These scores may therefore be better at predicting inflammation or chronicity than perfusion parameters. However, solid conclusions should not be drawn from post-hoc analyses. Also, it is important to notice that both scores include bowel wall thickness, which independently correlates even better than the total scores. This study has some limitations. First of all, the histopathological indices, considered gold standards, are semiquantitative by nature and have never been validated. Although used and slightly modified in different trials, they may not truly reflect disease activity/chronicity or susceptibility for medical treatment. As, by the nature of this complex disease, we do not have a true gold standard for grading activity or fibrosis, 43 our choice of gold standard was pragmatic. CEUS and DCE-MRE ROI placement may not have been completely identical to pathology analyses, due to blinding between modalities. However, the same segment was investigated and the most severe part of the segment chosen for analysis, in all three modalities. Since bowel wall thickness correlated well, we assume a good congruence for sites of analyses.
There is some selection bias in our study, since we did not include patients without inflammatory bowel changes. This is obviously owing to the fact that such patients would not undergo elective surgery. Additionally, there are several issues with the performance and reliability for dynamic perfusion in a bowel wall < 3 mm. 42 We aimed at grading activity rather than investigating presence of disease. For that purpose, we believe bowel wall thickness is sufficient. 50, 51 The importance of increased bowel wall perfusion within a bowel wall of less than 3 mm is still debatable. Our population was surprisingly heterogenous with regard to histopathology and biochemical activity. Some patients had mainly inflammation, some mainly fibrosis, and most had varying mixture of both, thus potentially allowing for a nice correlation with perfusion measurements.
Due to lack of correction for arterial input function, our methodology for measuring perfusion only allows relative or semiquantitative quantification. The impact of this is unknown, but using full deconvolution for bolus injection is extremely complex. 52 Jirik et al. 53 proposed a method to diminish this factor and achieve absolute quantification, which unfortunately has not yet been validated by others. The infusion-burst-replenishment technique could potentially overcome some of the limitations. Nevertheless, the method is expensive, cumbersome, and has not yet been used in inflammatory bowel disease [IBD] . These methods were inconsistent with our aim, which was to validate the two existing and relatively easy-to-perform methods: CEUS and DCE-MRE. The best future application of bolus-administered CEUS in CD may be in follow-up examinations on the same patient, since this will exclude between-patient variation. 54, 55 We did not apply Tofts pharmacokinetic model. However, as earlier discussed, fulfilment of the underlying assumptions for this model is also problematic. 21, 56 Finally, our study population is rather small. This may underestimate correlations between perfusion parameters and histological outcomes. However, our sample size was not largely different from others having investigated the same modalities. The fact that testing existing MRE scores was by post-hoc analysis will induce a risk of type I error, and these results should be investigated in separate prospective studies.
In conclusion, we found no correlation between relative perfusion measurements and histological grading of inflammatory activity or fibrosis. This could be due to the chosen gold standard and the complicated nature of perfusion measurements. Bowel wall thickness remains the single parameter that correlates best with both activity and fibrosis, and can be reliably estimated by MRE and especially US.
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